医药魔方2023-07-26 10:06
7月24日,Syndax Pharmaceuticals和Incyte共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
网页链接{点...查看全文
产业链观察2023-07-26 01:35
#药闻简讯# 7月24日,$Syndax制药(SNDX)$ 和$因塞特医疗(INCY)$ 共同宣布,抗CSF-1R单抗axatilimab在既往接受过二线及以上治疗后疾病进展的慢性移植物抗宿主病(GVHD)成人和儿童患者中的II期AGAVE-201研究取得了积极的关键数据。
AGAVE-201研究是一项随机、开放标签的II期临床试验,共纳入241...查看全文
SeekingBiotech2023-07-24 22:03
SNDX and Incyte announced topline data from the pivotal AGAVE-201 trial of axatilimab in adult and pediatric patients with chronic graft-versus-host disease (GVHD) following two or more prior lines of therapy. The trial achieved its primary endpoint across all cohorts
$S...查看全文
智通财经APP获悉,当地时间6月13日,美国FDA宣布批准礼来(LLY.US)和因塞特(INCY.US)联合开发的口服JAK抑制剂巴瑞替尼(英文商品名Olumiant)上市,用于治疗严重斑秃成人患者。值得一提的是,这是美国FDA批准用于治疗斑秃的首款系统性疗法... 网页链接
智通财经APP获悉,美国FDA于当地时间7月29日扩大了礼来(LLY.US)与因塞特医疗(INCY.US)的baricitinib药物(商用名Olumiant)的紧急适用授权(EUA)。根据修订后的EUA,治疗确诊新冠的住院患者时,baricitinib不需与吉利德科学(GILD.US)的Vekl... 网页链接
$因塞特医疗(INCY)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2016-03-17 AccNo: 0001144204-16-088726 Size: 193 KB 网页链接
$因塞特医疗(INCY)$ 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] Filed: 2016-03-15 AccNo: 0001558370-16-004172 Size: 3 MB 网页链接
$因塞特医疗(INCY)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-03-10 AccNo: 0000902219-16-001128 Size: 38 KB 网页链接
$因塞特医疗(INCY)$ 内部交易: 2016-02-25,EVP, Discovery Medicinal and P,Wenqing Yao ,期权,6566普通股, $18.32
$因塞特医疗(INCY)$ 8-K - Current report Filed: 2016-02-29 AccNo: 0001104659-16-100746 Size: 19 KBItem 8.01: Other Events 网页链接
$因塞特医疗(INCY)$ S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers Filed: 2016-02-24 AccNo: 0001104659-16-099624 Size: 958 KB 网页链接
$因塞特医疗(INCY)$ SC 13D/A [Amend] - General statement of acquisition of beneficial ownership Filed: 2016-02-16 AccNo: 0001144204-16-082849 Size: 197 KB 网页链接
$因塞特医疗(INCY)$ 内部交易: 2016-02-12,Director,BAKER JULIAN ,买入,922530普通股, $65.83
$因塞特医疗(INCY)$ 内部交易: 2016-02-11,Director,BAKER JULIAN ,买入,1328897普通股, $61.93
$因塞特医疗(INCY)$ 内部交易: 2016-02-16,Director,BAKER JULIAN ,买入,678488普通股, $70.71